Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREMICES neoadjuvant pembrolizumab watch-and-wait trial in dMMR/MSI-H localized colon cancer
2023-509322-22-00Phase 2Suspended
- Sponsor
- GERCOR
- Start
- Mar 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab in colon adenocarcinoma and rectal adenocarcinoma (2 arms), sponsored by GERCOR. Primary endpoint: Rate of success of the experimental strategy. Started Mar 2025; status: suspended.
02
Drugs
03
Conditions
colon adenocarcinomarectal adenocarcinoma
Beyond the preview
Go deeper on 2023-509322-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509322-22-00.